A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant
Starting soon · Phase 2
Conditions studied: Myeloid Disorders, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Acute Myeloid Leukemia
In brief
This is a prospective, open-label investigation to determine whether measurable residual disease (MRD) guided assignment of maintenance therapy is effective in patients with myeloid malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). Pre-HCT, patients will undergo usual disease assessments which should include immunophenotypic and/or molecular testing. Based on the results of these tests, patients may or may not be recommended to receive maintenance therapy post-transplant, depending on the presence or absence of a residual malignant clone.
Key facts
- Study ID
- NCT07572929
- Run by
- Medical College of Wisconsin
- People needed
- 450
- Starts
- 2026-08-01
- Expected to finish
- 2034-02-01
- Last updated by the study team
- 2026-06-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥18 years at time of transplant.
- Must have a diagnosis of a myeloid malignancy, myelodysplastic syndrome, myeloproliferative neoplasm (including primary or secondary myelofibrosis), or acute myeloid leukemia or biphenotypic acute leukemia.
- Pre-transplant disease assessment must include at least one:
- Immunophenotypic assessment by flow for aberrant blasts
- NGS to identify persistence of malignant clones using a standard clinically available assay
- PCR based measurement of prior identified mutations (if applicable)
- Ability to understand a written informed consent document, and the willingness to sign it.
You may not qualify if…
- None
Where it is running
- Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.